144 related articles for article (PubMed ID: 35199566)
1. NCAPG is a prognostic biomarker of immune infiltration in non-small-cell lung cancer.
Zhou Y; Fan Y; Mao Y; Lou M; Liu X; Yuan K; Tong J
Biomark Med; 2022 May; 16(7):523-535. PubMed ID: 35199566
[No Abstract] [Full Text] [Related]
2. Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
Xian H; Li Y; Zou B; Chen Y; Yin H; Li X; Pan Y
BMC Cancer; 2022 Jan; 22(1):107. PubMed ID: 35078435
[TBL] [Abstract][Full Text] [Related]
3. Role of ALOX5 in non-small cell lung cancer: A potential therapeutic target associated with immune cell infiltration.
Zhao Q; Sun Z; Pan Y; Jing Q; Li W; Wang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):311-322. PubMed ID: 37164914
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.
Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R
Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005
[TBL] [Abstract][Full Text] [Related]
5. APE1 may influence CD4+ naïve T cells on recurrence free survival in early stage NSCLC.
Li Y; Zhao X; Xiao H; Yang B; Liu J; Rao W; Dai X; Li M; Dai N; Yang Y; Wang D
BMC Cancer; 2021 Mar; 21(1):233. PubMed ID: 33676448
[TBL] [Abstract][Full Text] [Related]
6. NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression.
Sun H; Zhang H; Yan Y; Li Y; Che G; Zhou C; Nicot C; Ma H
Mol Cancer; 2022 Feb; 21(1):55. PubMed ID: 35180865
[TBL] [Abstract][Full Text] [Related]
7. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
8. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
9. Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer.
Li XT; Zhang JT; Yan HH; Su J; Cheng ML; Sun QH; Zhong WZ; Wu YL; Zhang DX; Hou DJ
Cancer Treat Res Commun; 2021; 26():100297. PubMed ID: 33385734
[TBL] [Abstract][Full Text] [Related]
10. PPM1D overexpression predicts poor prognosis in non-small cell lung cancer.
Yang H; Gao XY; Li P; Jiang TS
Tumour Biol; 2015 Mar; 36(3):2179-84. PubMed ID: 25412952
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
12. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
13. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
Li J; Li X; Zhang C; Zhang C; Wang H
Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer.
Wang D; Hao T; Pan Y; Qian X; Zhou D
Mol Cell Biochem; 2015 Apr; 402(1-2):75-82. PubMed ID: 25567207
[TBL] [Abstract][Full Text] [Related]
16. NCAPG as a Novel Prognostic Biomarker in Glioma.
Jiang X; Shi Y; Chen X; Xu H; Liu B; Zhou F; Huang X; Cho WC; Li L; Pu J
Front Oncol; 2022; 12():831438. PubMed ID: 35280743
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis and experimental validation of TTK as a biomarker for prognosis in non-small cell lung cancer.
Chen J; Wu R; Xuan Y; Jiang M; Zeng Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969465
[TBL] [Abstract][Full Text] [Related]
19. NCAPG is a prognostic biomarker associated with vascular invasion in hepatocellular carcinoma.
Guo ZY; Zhu ZT
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7238-7251. PubMed ID: 34919223
[TBL] [Abstract][Full Text] [Related]
20. LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma.
Piao L; Yang Z; Feng Y; Zhang C; Cui C; Xuan Y
BMC Cancer; 2019 Sep; 19(1):898. PubMed ID: 31500591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
